New cocktail targets tough pancreatic cancer in early trial
NCT ID NCT06896188
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a three-part drug combination for people with advanced pancreatic cancer who haven't had chemotherapy yet. The drugs include elraglusib (a targeted agent), retifanlimab (an immunotherapy), and a standard chemo regimen called mFOLFIRINOX. The main goal is to check safety and find the right dose in up to 12 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elraglusib (9-ING-41) combined with retifanlimab and chemotherapy (oxaliplatin, leucovorin, irinotecan, 5-FU)
What this could lead to
If this combination proves safe, it could point toward a more effective first-line treatment for advanced pancreatic cancer, potentially improving disease control.
What could go wrong
This is a very early phase 1 trial with only 12 patients, focused on safety. The drug combo may cause severe side effects or fail to shrink tumors. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••